Therefore, FLT3 tyrosine kinase inhibitors (TKIs) such as quizartinib, midostaurin, or gilteritinib are logical choices for treatment in FLT3+ AML [3,4]. This evidence concerns the gene FLT3 and acute myeloid leukemia.